MTA-SZTE Research Group on Artificial Intelligence
SZTE Publicatio Repozitórium - SZTE - Repository of PublicationsNot a member yet
32192 research outputs found
Sort by
The role of family environment and school climate in shaping adolescent well-being: The mediating role of positive youth development
No full textEpcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1) : a global, open-label, randomised, phase 3 trial
Full text linkAn unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R2) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus R2 versus R2 in participants with relapsed or refractory follicular lymphoma after at least one previous line of chemoimmunotherapy.In this multicountry, open-label, phase 3 trial, participants were randomly allocated (1:1) to fixed-duration epcoritamab plus R2 or R2 for up to 12 cycles. Epcoritamab was administered weekly in cycles 1-3 and every 4 weeks in cycles 4-12, lenalidomide once daily during cycles 1-12 (days 1-21), and rituximab weekly during cycle 1 and monthly in cycles 2-5. The dual primary endpoints were overall response rate and progression-free survival by independent review committee. The data reported here are from a planned interim analysis carried out after 78% of progression-free survival events had occurred. This study is registered with ClinicalTrials.gov, NCT05409066, and EudraCT, 2021-000169-34, and is ongoing (closed to recruitment).Out of 668 participants screened for eligibility across 189 academic and non-academic centres in 30 countries across Africa, Asia, Australia, Europe, North America, and South America, a total of 488 participants were randomly allocated, 243 to epcoritamab plus R2 and 245 to R2. The trial met its dual primary endpoints, showing superiority of epcoritamab plus R2 over R2 in overall response rate and progression-free survival. With a median follow-up of 14·8 months (IQR 11·4-19·0), overall response rate was 95% (95% CI 92-97) with epcoritamab plus R2 versus 79% (74-84; p<0·0001) with R2. Progression-free survival was longer with epcoritamab plus R2 versus R2 (hazard ratio 0·21 [95% CI 0·14-0·31], p<0·0001); estimated 16-month progression-free survival favoured epcoritamab plus R2 (85·5% vs 40·2%). Grade 3 or higher adverse events were more frequent with epcoritamab plus R2 (219 [90%] of 243 participants) versus R2 (161 [68%] of 238 participants). Cytokine release syndrome was low grade with epcoritamab plus R2 (grade 1 in 28 [21%] participants and grade 2 in seven [5%] participants) and manageable, and all events were resolved.Epcoritamab plus R2 resulted in significantly higher response rate and longer progression-free survival versus R2 among participants with follicular lymphoma who had received at least one line of therapy. Epcoritamab plus R2 had more grade 3 or higher adverse events versus R2. Adverse events were manageable and consistent with the established safety profiles of the individual components, with no new safety findings identified. These findings position epcoritamab plus R2 as a new standard of care for second-line or subsequent treatment of follicular lymphoma.AbbVie and Genmab
A cross-national assessment on critical thinking disposition between Hungarian and Chinese undergraduate students
No full textGenetic differences in familial adenomatous polyposis syndrome in a Hungarian population: A prospective single center study
Full text linkVedolizumab in early and late Crohn's disease (LOVE-CD) : a phase 4 open-label cohort study
Full text linkVedolizumab is efficacious in inducing and maintaining clinical remission in Crohn's disease. However, prospective data about its efficacy in early Crohn's disease are scarce. We aimed to evaluate the ability of vedolizumab to promote clinical, endoscopic, and histological remission in patients with early and late active Crohn's disease over a 1-year period.This phase 4 investigator-initiated, open-label cohort study was conducted at 22 hospitals in Belgium, Hungary, and the Netherlands. Eligible patients were adults aged 18-80 years with moderate to severe Crohn's disease (Crohn's Disease Activity Index [CDAI] 220-450, with ulcers at endoscopy). Patients were divided into two groups: those with early Crohn's disease (defined as a diagnosis less than 2 years ago and naive to advanced treatment [naive or only treated with corticosteroids or immunomodulators, or both]); and those with late Crohn's disease (defined as a diagnosis more than 2 years ago and previously treated with corticosteroids, immunomodulators, and anti-TNF agents). Patients received intravenous vedolizumab (300 mg) at weeks 0, 2, and 6, and every 8 weeks thereafter for 52 weeks, with an additional 300 mg infusion at week 10 in the absence of a decrease in CDAI of more than 70 at week 6. Colonoscopies with biopsies were done at screening, week 26, and week 52, and assessed by masked independent readers with the Simple Endoscopic Score for Crohn's disease (SES-CD). The primary endpoint was the proportion of patients with clinical and endoscopic remission (defined as CDAI ≤150 and SES-CD <4) at both week 26 and 52. Primary and safety analyses included patients who received at least one dose of the study drug. This study is registered on the EU Clinical Trial Register (EudraCT; 2014-005376-29) and is now completed.Between July 10, 2015, and July 1, 2022, 86 patients with early Crohn's disease (45 [52·3%] female and 41 [47·7%] male) and 174 with late Crohn's disease (111 [63·8%] female and 63 [36·2%] male) were enrolled. Clinical and endoscopic remission at both week 26 and 52 was achieved in 27 (31·4%) of 86 patients with early Crohn's disease versus 15 (8·6%) of 174 patients with late Crohn's disease (difference 22·8%, 95% CI 12·6-33·7). Serious adverse events occurred in three (3·5%) of 86 patients with early Crohn's disease versus 46 (26·4%) of 174 patients with late Crohn's disease and included infections (one [1·2%] vs 13 [7·5%]), surgery (none vs eight [4·6%]), intestinal obstruction (none vs four [2·3%]), exacerbation of Crohn's disease (one [1·2%] vs six [3·4%]), and malignancy (none vs three [1·7%]).Vedolizumab treatment is safer and more effective in early than in late Crohn's disease. Vedolizumab could be considered as a favourable treatment option for patients with biologic-naive Crohn's disease with a short disease duration.Takeda Nederland
How are Lao teachers’ goals for teaching associated with their instructional practices?
Full text linkImpact of Chest Wall on Respiratory Mechanics, Ventilation and Ventilation–Perfusion Matching During Cardiac Surgery
No full textKrónikus, teljes koszorúér-elzáródás rekanalizációja transradialis behatolásból
Full text linkCélkitűzés: Tudományos munkánk célja volt megvizsgálni a transradialis behatolás biztonságosságát és hatékonyságát krónikus teljes coronariaocclusio rekanalizációjában. Módszer: 2016 és 2019 között két cardiovascularis centrumban összesen 308 krónikus teljes coronariaocclusiós beteget vontunk be prospektív vizsgálatunkba. A transfemoralis behatolásból végzett eseteket kizártuk, így 272, transradialis behatolásból végzett krónikus teljes coronariaelzáródás miatt coronaria intervención átesett beteg adatait dolgoztuk fel. Procedurálisan sikeresnek tekintettük a beavatkozást, ha <50%-os reziduális szűkület maradt vissza a beavatkozás végén. Vizsgáltuk a beavatkozás sikerességét, a major cardialis és cerebralis események előfordulásának gyakoriságát, a vascularis komplikációk arányát, a procedurális faktorokat. Eredmények: A 3 éves vizsgálati periódusban 272, komplex krónikus teljes coronariaocclusiós eset percutan coronariaintervencióját végeztük el transradialis behatolásból. A betegek átlagéletkora 73 ± 9 év volt, és 74%-uk volt férfi. A procedurális siker 83,4%, míg a technikai siker aránya 64,7% volt. A major cardialis és cerebralis események 1 éves előfordulása 15,6%, a vascularis szövődmények előfordulása 2,57% volt. Procedurális komplikációt 4,78%-ban észleltünk. Az esetek 1,8%-ában volt szükség technikai okok miatt transradialisról transfemoralisra váltani a beavatkozás alatt. Az átlagos kontrasztanyag-felhasználás 178 ml (176–211), az átlagos procedurális idő 52,3 min (51,3–66,2) és a sugárdózis 2140,5 (2110–2998) mGy volt. Következtetés: Eredményeink alapján elmondható, hogy a transradialis behatolásból végzett krónikus teljes coronariaelzáródás percutan intervenciója biztonságos és sikeres beavatkozás, amely elfogadható arányú szövődményrátával társul. Orv Hetil. 2026; 167(1): 16–22